Comparison of bypassing agents in patients on emicizumab using global hemostasis assays
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14213
Abstract: Emicizumab is a humanized bispecific monoclonal antibody licensed for patients with severe haemophilia A with and without inhibitors. Management of breakthrough bleeding in patients with inhibitors on emicizumab involves episodic treatment with bypassing agents (BPA),… read more here.
Keywords: patients emicizumab; comparison bypassing; agents patients; bypassing agents ... See more keywords
Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14684
Abstract: Emicizumab is a humanized bispecific monoclonal antibody licensed for patients with severe haemophilia A. Breakthrough bleeding still occurs in patients on emicizumab and can be managed with recombinant factor VIIa (rFVIIa) or activated prothrombin complex… read more here.
Keywords: safety; complex concentrate; patients emicizumab; prothrombin complex ... See more keywords